Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan D Berlin

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyBert H O'Neil, Robert Allen, David R Spigel, et al.
American Journal of Clinical Oncology|October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignanciesLaura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Investigational New Drugs|March 30, 2017
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRASEmily Chan, Laura W Goff, Dana B Cardin, et al.
The Oncologist|December 13, 2025
Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registryRajiv Agarwal, Jennifer G Whisenant, Lili Sun, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Oncology|June 26, 2004
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology groupRobert C Shepard, Donna E Levy, Jordan D Berlin, et al.
American Journal of Clinical Oncology|March 17, 2017
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic CancerDana B Cardin, Ramya Thota, Laura W Goff, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
American Journal of Clinical Oncology|January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancerEmily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal TumorsAnna M Varghese, Dana B Cardin, Jonathan Hersch, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyBert H O'Neil, Robert Allen, David R Spigel, et al.
American Journal of Clinical Oncology|October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignanciesLaura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Investigational New Drugs|March 30, 2017
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRASEmily Chan, Laura W Goff, Dana B Cardin, et al.
The Oncologist|December 13, 2025
Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registryRajiv Agarwal, Jennifer G Whisenant, Lili Sun, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Oncology|June 26, 2004
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology groupRobert C Shepard, Donna E Levy, Jordan D Berlin, et al.
American Journal of Clinical Oncology|March 17, 2017
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic CancerDana B Cardin, Ramya Thota, Laura W Goff, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
American Journal of Clinical Oncology|January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancerEmily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal TumorsAnna M Varghese, Dana B Cardin, Jonathan Hersch, et al.
Pageof 9